Biotechnology Market Overview Analysis By Fortune Business Insights Analysis
Market Summary
According to Fortune Business Insights: The global biotechnology market size was valued at USD 1,376.1 billion in 2025 and is projected to grow from USD 1,491.5 billion in 2026 to USD 4,334.8 billion by 2034, exhibiting a CAGR of 14.3% during the forecast period. North America dominated the biotechnology market with a market share of 43.34% in 2025.
Key Market Trends
Single-use and flexible manufacturing is a defining trend, with single-use systems used in 87% of biopharma manufacturing facilities in 2024 (BioPlan Associates). In March 2025, Cytiva expanded its Xcellerex X-platform with 500 L and 2,000 L single-use bioreactors. AI is also compressing timelines: target identification that took 3 to 6 years may now take 1 to 2 years. Insilico Medicine developed an idiopathic pulmonary fibrosis drug candidate in 18 months, and Exscientia designed a potent PKC-Theta inhibitor in 11 months.
Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/116041
Key Market Drivers
Demand for biopharmaceuticals is the main driver. Biologics offer higher efficacy, better target specificity, and improved safety than small molecules, which supports premium pricing and favorable reimbursement. Six of the top 10 best-selling drugs in the first half of 2025 were biopharmaceuticals: Keytruda, Mounjaro, Dupixent, Skyrizi, Darzalex, and Opdivo.
Market Restraints
High R&D costs and failure rates weigh on the market. Small molecule drugs take 8 to 10 years and USD 1 to 2 billion to develop, while biologics take 10 to 12 years and USD 2 to 4 billion. Regulatory complexity adds friction, as requirements differ across the FDA, EMA, and India's CDSCO and can delay global launches. Bluebird bio's gene therapies faced years of regulatory delays over cancer risk from viral vectors, requiring follow-up studies of up to 15 years. Funding is also tighter: venture capital reached about USD 34 billion in 2025, versus USD 56 billion in 2021.
Market Opportunities
Sustainable production is a clear opening, as bio-based chemicals, enzymes, and advanced biofuels gain adoption to cut emissions and waste. Large rounds show investor appetite for the right platforms, including Xaira Therapeutics (USD 1 billion), Treeline Biosciences (USD 0.42 billion), Kailera Therapeutics (USD 0.40 billion), and Formation Bio (USD 0.37 billion) in 2024.
Segmentation Analysis
By technology, bioprocessing technologies were the largest segment in 2025, while genomics and genetic analysis is expected to grow at a 12.1% CAGR. Other segments include synthetic biology and genetic engineering, gene editing, cell engineering and cell culture, and nanobiotechnology. By application, biopharmaceutical discovery and preclinical research was the largest in 2025, while cell and gene therapy is expected to grow fastest at a 19.7% CAGR, alongside molecular diagnostics, industrial biotechnology, RNA therapeutics, precision medicine, and regenerative medicine. By end user, pharmaceutical and biotech companies are the largest, with a projected 53.8% share in 2026, while CROs and CDMOs are expected to grow at a 17.5% CAGR.
Regional Outlook
North America led the market with a 43.34% share in 2025 (USD 596.5 billion, up from USD 554.8 billion in 2024), with the U.S. at USD 615.5 billion in 2026, about 41.3% of global revenue.
Europe is projected at USD 386.6 billion in 2026 and growing at a 14.0% CAGR, with the U.K. at USD 86.4 billion and Germany at USD 79.1 billion.
Asia Pacific, the third-largest region, is projected at USD 293.9 billion in 2026, with China at USD 88.3 billion, Japan at about USD 54.0 billion, and India at about USD 52.3 billion.
Latin America is projected at USD 86.2 billion in 2026, the GCC at USD 32.2 billion, and South Africa at about USD 29.9 billion.
Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/116041
Competitive Landscape
The Eli Lilly and AbbVie as leaders, Amgen and Gilead Sciences as challengers, Moderna and BioNTech as visionaries, and Genmab and Insmed as niche players. Other profiled companies include Hoffmann-La Roche, Pfizer, AstraZeneca, Vertex, Alnylam, argenx, and CELLTRION.
In January 2026, Sartorius expanded its bio-based single-use fluid management portfolio, and in December 2025 Thermo Fisher expanded its Bioprocess Design Centers across Asia, including a new center in Hyderabad.
In September 2025, Merck KGaA opened a USD 176.8 million filtration facility in Cork, and Agilent released Altura Ultra Inert HPLC Columns for biotherapeutics testing.
In August 2025, Cytiva and Culture Biosciences expanded their collaboration to commercialize the Stratyx 250 hardware globally. Capacity investments continue, with FUJIFILM announcing USD 1.2 billion for cell-culture CDMO expansion in North Carolina in April 2024 and Johnson & Johnson announcing over USD 2 billion for a biologics facility there in October 2024.
Explore Japan’s Market Opportunities - Latest Biotechnology Market Insights